Overview of the Origin and Application of Obeticholic Acid

Obeticholic acid (Obeticholic acid) is a semi-synthetic compound whose roots can be traced back to natural bile acids and chenodeoxycholic acid. Chenodeoxycholic acid plays an important role in the human body. It is a natural ligand of the farnesoid X receptor (FXR). FXR is regarded as a type of nuclear hormone receptor. It is mainly expressed in the nucleus of liver and intestinal cells and plays a key regulatory role. In intestinal cells, FXR activity regulates bile acid synthesis through the release of fibroblast growth factor (FGF-19), thereby maintaining bile acid balance. In hepatocytes, FXR is involved in regulating liver inflammation, fibrosis, metabolic pathways, and regeneration processes.

Primary biliary cholangitis (PBC), once known as primary biliary cirrhosis, is a chronically progressive liver disease. It gradually damages the bile ducts in the liver, which can lead to cirrhosis and liver failure. The disease may be asymptomatic for many years in its early stages, but gradually worsens over time. The emergence of obeticholic acid provides a new option for the treatment of this disease. It is primarily used to treat adult patients with primary biliary cholangitis who have not yet developed cirrhosis. In some cases, obeticholic acid may be combined with another drug, ursodeoxycholic acid (UDCA), to enhance the effectiveness of the treatment. In addition, obeticholic acid may be used for other therapeutic purposes not listed in this Medication Guide.

Therefore, obeticholic acid is derived from natural chenodeoxycholic acid and is made semi-synthetically. As a potent farnesoid X receptor agonist, it has shown significant efficacy in the treatment of cholestatic diseases such as primary cholangitis, providing a new treatment option for patients who have poor response to traditional treatments.